Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

The endpoint in cancer research is overall survival. Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used. Measurement of response rate in hepatocellular carcinoma (HCC) has become a controversial issue. The World Health Organization (WHO) criteria underestimate the actual response rate; thus, they were amended in 2000 by a panel of experts convened by the European Association for the Study of the Liver (EASL) to take into account treatment-induced tumor necrosis. Applying these guidelines, there was an association between response rate and outcome prediction. More recently, the Response Evaluation Criteria in Solid Tumors (RECIST) guideline was…

• SW
  Samuel Waxman Cancer Research Foundation
• NI
  National Institute of Diabetes and Digestive and Kidney Diseases

  Award: 1R01DK076986-01